Literature DB >> 4318282

Cortisol and growth hormone secretion in relation to linear growth: patients with Still's disease on different therapeutic regimens.

R A Sturge, C Beardwell, M Hartog, D Wright, B M Ansell.   

Abstract

Linear growth was studied in 20 children suffering from Still's disease on various treatment regimens, and their ability to secrete growth hormone and cortisol was investigated. Growth recovered on reducing daily corticosteroid therapy or on changing to an alternative regimen. Retardation of growth was not due to an absolute inability to secrete growth hormone. Basal plasma cortisol levels and the plasma cortisol response to hypoglycaemia were reduced in patients on daily steroid therapy, but patients on alternate-day prednisone did not differ significantly in this respect from those on non-steroid regimens. Those on alternate-day corticotrophin showed preservation of the circadian rhythm but a subnormal response to hypoglycaemia.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4318282      PMCID: PMC1701579          DOI: 10.1136/bmj.3.5722.547

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  28 in total

1.  Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children.

Authors:  F M BLODGETT; L BURGIN; D IEZZONI; D GRIBETZ; N B TALBOT
Journal:  N Engl J Med       Date:  1956-04-05       Impact factor: 91.245

2.  Growth in Still's disease.

Authors:  B M ANSELL; E G BYWATERS
Journal:  Ann Rheum Dis       Date:  1956-12       Impact factor: 19.103

3.  Hypothalamo-pituitary-adrenal function in patients on long-term adrenocorticotrophin therapy.

Authors:  P A Bacon; J R Daly; A B Myles; O Savage
Journal:  Ann Rheum Dis       Date:  1968-01       Impact factor: 19.103

4.  Effect of corticotorphin on skeletal maturation and linear growth in six patients with severe asthma.

Authors:  A P Norman; S Sanders
Journal:  Lancet       Date:  1969-02-08       Impact factor: 79.321

5.  Adrenocortical responsiveness after alternate-day corticosteroid therapy.

Authors:  G L Ackerman; C M Nolsn
Journal:  N Engl J Med       Date:  1968-02-22       Impact factor: 91.245

6.  Corticosteroid-induced hypothalamo-pituitary-adrenal axis suppression. Prospective study using two regimens of corticosteroid therapy.

Authors:  K M Jasani; J A Boyle; W C Dick; J Williamson; A K Taylor; W W Buchanan
Journal:  Ann Rheum Dis       Date:  1968-07       Impact factor: 19.103

7.  Growth hormone secretion provoked by insulin-induced hypoglycaemia in children of short stature.

Authors:  L Stimmler; G A Brown
Journal:  Arch Dis Child       Date:  1967-06       Impact factor: 3.791

8.  Growth hormone and growth.

Authors:  M M Grumbach
Journal:  Pediatrics       Date:  1966-02       Impact factor: 7.124

9.  Studies of growth hormone secretion in children: normal, hypopituitary and constitutionally delayed.

Authors:  L A Frohman; T Aceto; M H MacGillivray
Journal:  J Clin Endocrinol Metab       Date:  1967-10       Impact factor: 5.958

10.  Plasma growth hormone concentration in corticosteroid-treated children.

Authors:  H G Morris; J R Jorgensen; S A Jenkins
Journal:  J Clin Invest       Date:  1968-03       Impact factor: 14.808

View more
  14 in total

1.  Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.

Authors:  F De Benedetti; T Alonzi; A Moretta; D Lazzaro; P Costa; V Poli; A Martini; G Ciliberto; E Fattori
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Growth and skeletal maturation in congenital adrenal hyperplasia. Review of 20 cases.

Authors:  C C Bailey; G M Komrower
Journal:  Arch Dis Child       Date:  1974-01       Impact factor: 3.791

3.  Corticotrophin therapy in juvenile chronic polyarthritis (Still's disease) and effect on growth.

Authors:  D W Zutshi; M Friedman; B M Ansell
Journal:  Arch Dis Child       Date:  1971-10       Impact factor: 3.791

4.  Growth hormone studies in patients with rheumatoid arthritis with or without glucocorticoid therapy.

Authors:  O Butenandt; A Kelch; E Rajmann
Journal:  Z Kinderheilkd       Date:  1974

5.  Rheumatoid arthritis and growth retardation in children: treatment with human growth hormone.

Authors:  O Butenandt
Journal:  Eur J Pediatr       Date:  1979-01-18       Impact factor: 3.183

6.  Glucocorticosteroids and growth hormone secretion under physiological conditions and in states of steroid excess.

Authors:  K E Mühlendahl; B Weber; R Müller-Hess; S Korth-Schütz; H Helge
Journal:  Eur J Pediatr       Date:  1978-06-20       Impact factor: 3.183

7.  Low cortisol levels in active juvenile idiopathic arthritis.

Authors:  Yelda Bilginer; Rezan Topaloglu; Ayfer Alikasifoglu; Nazli Kara; Nesrin Besbas; Seza Ozen; Aysin Bakkaloglu
Journal:  Clin Rheumatol       Date:  2009-12-15       Impact factor: 2.980

8.  Serum 25 (OH) D and 24,25 (OH)2 levels in childhood nephrosis under different therapeutic regimens of steroid administration.

Authors:  K Kano; T Suda
Journal:  Eur J Pediatr       Date:  1982-03       Impact factor: 3.183

9.  Growth and endocrine function in steroid sensitive nephrotic syndrome.

Authors:  L Rees; S A Greene; P Adlard; J Jones; G B Haycock; S P Rigden; M Preece; C Chantler
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

10.  Interactions between growth hormone and dexamethasone in skeletal growth and bone structure of the young mouse.

Authors:  A Altman; Z Hochberg; M Silbermann
Journal:  Calcif Tissue Int       Date:  1992-10       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.